Sanofi diet drug fails to slow heart disease

New Sanofi-Aventis diet and weight-loss drug rimonabant has been found not to have a sufficiently positive influence on slowing heart disease, in study on obese patients with high abdominal fat levels. Furthermore, the drug was found to increase levels of anxiety and depression according to an American research tem.
The drug, which is available as Acomplia in Europe, caused psychiatric problems amongst 40 per cent of patients, a research team told the American College of Cardiology .
Patients who took rimonabant did, however, improve in another measure of coronary artery disease, meaning that the drug could warrant further research. Dr. Nissen of the Cleveland Clinic was reported in the news as commenting: “What you have here is some mixed evidence for a slowing of progression and a definite increase in psychiatric adverse events.”

Related Articles